RSLS — ReShape Lifesciences Balance Sheet
0.000.00%
- $4.74m
- $4.85m
- $8.01m
- 35
- 45
- 28
- 28
Annual balance sheet for ReShape Lifesciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 3.9 | 22.8 | 3.85 | 4.46 | 0.693 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3.15 | 2.81 | 2.18 | 1.66 | 1.03 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 7.83 | 29.9 | 9.91 | 10.3 | 4.59 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.48 | 1.72 | 0.869 | 0.31 | 0.154 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 10.6 | 52.5 | 11.1 | 10.7 | 4.79 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5.05 | 7.53 | 7.48 | 3.78 | 4.99 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 5.95 | 8.2 | 7.48 | 4 | 5.05 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 4.67 | 44.3 | 3.66 | 6.66 | -0.253 |
Total Liabilities & Shareholders' Equity | 10.6 | 52.5 | 11.1 | 10.7 | 4.79 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |